Loading…
Abbott Laboratories is projected to rise to $106.35 by 2027, a +13% move from its current price of $93.93. ABT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $92.66 | $93.94 | $95.24 | +0.01% |
| Jul 13 | $92.15 | $93.96 | $95.80 | +0.03% |
| Jul 14 | $91.76 | $93.97 | $96.23 | +0.04% |
| Jul 15 | $91.44 | $93.98 | $96.60 | +0.05% |
| Jul 16 | $91.15 | $93.99 | $96.92 | +0.07% |
| Jul 17 | $90.90 | $94.01 | $97.22 | +0.08% |
| Jul 18 | $90.67 | $94.02 | $97.49 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $90.67 | $94.02 | $97.49 | +0.10% |
| Week 2 | $89.40 | $94.11 | $99.07 | +0.19% |
| Week 3 | $88.46 | $94.20 | $100.31 | +0.29% |
| Week 4 | $87.69 | $94.29 | $101.39 | +0.38% |
| Week 5 | $87.02 | $94.38 | $102.36 | +0.48% |
| Week 6 | $86.43 | $94.47 | $103.25 | +0.57% |
| Week 7 | $85.90 | $94.56 | $104.09 | +0.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.
In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Abbott Laboratories (ABT) is a Healthcare company with a broad portfolio spanning pharmaceuticals, diagnostics, nutrition, and medical devices. Its current price is $94.12 and its market capitalization stands at $163.94B, with a market rank of 90.
The forecast path suggests a steady rise in the average price over the coming years, starting near the current level and moving higher into the next decade, culminating in substantial upside by 2050. The trajectory includes pronounced gains in the 2030s and beyond, reflecting expanding value and investor optimism in the long horizon.
A major floor 13.2% below — a decisive break under it would weaken the trend.
The nearest floor, 8.9% below — buyers have tended to step in here.
Price is pressing into resistance (2.0% away) — a breakout level to watch.
A major ceiling 21.0% above — clearing it would confirm fresh momentum.
Key ABT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $95.00 | Sell | $94.40 | Sell |
| MA 10 | $94.01 | Sell | $93.78 | Buy |
| MA 20 | $91.81 | Buy | $92.47 | Buy |
| MA 50 | $89.19 | Buy | $92.43 | Buy |
| MA 100 | $97.28 | Sell | $97.41 | Sell |
| MA 200 | $110.83 | Sell | $105.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.61 | Neutral |
| Stoch RSI (14) | 60.78 | Neutral |
| CCI (20) | 57.61 | Neutral |
| Williams %R (14) | -23.85 | Info |
| MACD (12,26,9) | 0.29 | Buy |
| ROC (12) | 3.76 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 76.15 | Neutral |
| TRIX (15) | 0.21 | Buy |
| Awesome (5,34) | 4.70 | Buy |
| Ultimate (7,14,28) | 69.28 | Neutral |
| Momentum (10) | 0.69 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 95.22 | Sell |
| ADX (14) | 16.97 | Neutral |
| ATR (14) | 1.15 | Info |
30-day technical picture: sentiment is BULLISH and the RSI14 is 60.
The 50-day simple moving average is $89.27 and the 200-day simple moving average is $112.80. Support is at $83.83 and resistance at $93.24. The 30-day price range spans from $85.32 to $103.83, framing near-term volatility within an upward bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $82.56 | $93.93 | $117.35 | 0% | Neutral | |
| $87.10 | $106.35 | $135.77 | +13% | Neutral | |
| $91.69 | $114.07 | $149.56 | +21% | Bullish | |
| $91.40 | $115.46 | $154.60 | +23% | Bullish | |
| $100.59 | $128.78 | $175.55 | +37% | Bullish | |
| $111.88 | $144.98 | $200.75 | +54% | Bullish | |
| $125.48 | $164.44 | $230.93 | +75% | Bullish | |
| $137.60 | $182.22 | $259.22 | +94% | Bullish | |
| $135.19 | $180.81 | $260.30 | +93% | Bullish | |
| $137.79 | $186.04 | $270.80 | +98% | Bullish | |
| $198.91 | $280.10 | $427.26 | +198% | Bullish | |
| $346.02 | $522.58 | $854.46 | +456% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $82.56 | $93.93 | $112.39 | +0.00% |
| August 2026 | $80.67 | $94.44 | $112.96 | +0.54% |
| September 2026 | $80.85 | $95.11 | $114.64 | +0.71% |
| October 2026 | $82.49 | $97.43 | $118.22 | +2.44% |
| November 2026 | $81.99 | $97.18 | $118.56 | -0.26% |
| December 2026 | $80.48 | $95.70 | $117.35 | -1.53% |
Click any year to see its month-by-month ABT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ABT could reach as high as $117.35, with a base case around $93.93 and support toward $82.56 — roughly 0% from $93.93. Price action looks broadly range-bound.
Expect ABT to range from $87.10 to $135.77 through 2027. The $106.35 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. A consolidation phase looks the most probable path here.
The ABT price prediction for 2028 points to an average of $114.07 (low $91.69, high $149.56) — a potential gain of +21% on today's $93.93. Momentum favours further upside here.
In 2029, ABT is projected to trade between $91.40 and $154.60, averaging $115.46 — a potential gain of +23% from today's $93.93. That is up +1% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Abbott Laboratories's 2030 outlook centres on $128.78, within a $100.59 to $175.55 range. That is up +12% on the projected 2029 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2031, ABT could reach as high as $200.75, with a base case around $144.98 and support toward $111.88 — roughly +54% from $93.93. Buyers look set to stay in control over this stretch.
Expect ABT to range from $125.48 to $230.93 through 2032. The $164.44 average target implies a +75% move from current prices. That is up +13% on the projected 2031 average. Momentum favours further upside here.
The ABT price prediction for 2033 points to an average of $182.22 (low $137.60, high $259.22) — a potential gain of +94% on today's $93.93. Buyers look set to stay in control over this stretch.
In 2034, ABT is projected to trade between $135.19 and $260.30, averaging $180.81 — a potential gain of +93% from today's $93.93. That is -1% versus the projected 2033 average. Momentum favours further upside here.
Abbott Laboratories's 2035 outlook centres on $186.04, within a $137.79 to $270.80 range. That is up +3% on the projected 2034 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ABT could reach as high as $427.26, with a base case around $280.10 and support toward $198.91 — roughly +198% from $93.93. Momentum favours further upside here.
Expect ABT to range from $346.02 to $854.46 through 2050. The $522.58 average target implies a +456% move from current prices. That is up +87% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABT today (≈ 10.646226 ABT) could be worth
$5,563.45
+$4,563.45 (+456%) by 2050 · US Dollar
Based on the average projected ABT price of $522.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABTwould be worth at today's price.
$1,000 invested in ABT on Jul 10, 2025 (≈ 7.48503 ABT) would be worth
$703.07
-$296.93 (-29.7%) today · 0.70× · US Dollar
Based on a ABT entry price of $133.6 vs. today's $93.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $95.4 | $984.59 | -1.5% |
| 1 month ago | $89.17 | $1,053.38 | +5.3% |
| 3 months ago | $100.3 | $936.49 | -6.4% |
| 6 months ago | $124.64 | $753.61 | -24.6% |
| 1 year ago | $133.6 | $703.07 | -29.7% |
| All time (5.0y) ago | $118.81 | $790.59 | -20.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABT forecast.
Our base-case forecast reaches $190.00 around 2040.
Implied market cap at $190.00: $330.94B
The multi-year forecast shows bullish momentum building after 2026, with several years of meaningful upside. The 2026 forecast is neutral with an average price of $94.12 and a broad range from $82.56 to $118.19, while subsequent years turn bullish.
By 2030, the average price is projected to be $129.67, with a min of $101.24 and a max of $176.87, and an ROI of 37.8. The sentiment remains BULLISH, with steady upside through 2031 ($144.92 avg) and 2032 ($165.27 avg), and continuing through 2035 ($186.29 avg).
Longer horizon targets show substantial gains: by 2040 the average price is $276.82 with a max of $422.40 and ROI of 194.1, and by 2050 the average price is $523.79 with a max of $856.64 and ROI of 456.5, all labeled as BULLISH. These figures imply a durable, long-run appreciation path but remain subject to market and company-specific risks and uncertainties.
Tap a question to reveal the answer.
Avg price $129.67; min $101.24; max $176.87; ROI 37.8; sentiment BULLISH.
Yes, the 2031 max forecast is $200.78; 2031 avg is $144.92; min $111.78; ROI 54; sentiment BULLISH.
Avg $276.82; min $196.53; max $422.40; ROI 194.1; sentiment BULLISH.
Avg $523.79; min $346.74; max $856.64; ROI 456.5; sentiment BULLISH.
The 30-day technical picture shows bullish sentiment; RSI14 is 60. The 30-day range is $85.32-$103.83, with SMA50 $89.27 and SMA200 $112.80. Support sits at $83.83 and resistance at $93.24.
Abbott Laboratories Community Discussion
0Share your Abbott Laboratories price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.